Fenwick & West represented Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options, in its initial public offering of common stock at a public offering price of $18.00 per share for total offering gross proceeds of $248.4 million, before underwriting discounts and commissions and other offering expenses payable by Passage Bio.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Chardan acted as lead manager for the offering.
More information can be obtained from Passage Bio’s announcement.
The Fenwick transaction team includes corporate partners Effie Toshav, Robert Freedman and Matthew Rossiter and associates Ryan Mitteness, Chelsea Anderson, Matthew McCabe, Derrick Chapman and Adam Conway; employee benefits and executive compensation partner Elizabeth Gartland and associates Sarah Ghulamhussain and Laura McIntyre; intellectual property partner Daniel Becker and associate Hayan Yoon; licensing attorney Amy Manning; and IP litigation partners David Tellekson and Robert Counihan.